Arizest Pharma (India) Profile
Key Indicators
- Authorised Capital ₹ 75.00 Cr
as on 30-07-2024
- Paid Up Capital ₹ 66.34 Cr
as on 30-07-2024
- Company Age 9 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 40.00 Cr
as on 30-07-2024
- Revenue 0.94%
(FY 2023)
- Profit -1.29%
(FY 2023)
- Ebitda -3.18%
(FY 2023)
- Net Worth -13.23%
(FY 2023)
- Total Assets -4.48%
(FY 2023)
About Arizest Pharma (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 75.00 Cr and a paid-up capital of Rs 66.34 Cr.
The company currently has active open charges totaling ₹40.00 Cr.
The Key Managerial Personnel (KMP) at Arizest Pharma (India) Private Limited India is Makkigadde Shreepada as COMPANY SECRETARY. Manorama Avinash and Chinnasamy Anbarasu serve as directors at the Company.
- CIN/LLPIN
U24100KA2015FTC080832
- Company No.
080832
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
11 Jun 2015
- Date of AGM
28 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bengaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Arizest Pharma (India)?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Makkigadde Shreepada | Company Secretary | 29-Jun-2023 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manorama Avinash  | Director | 11-Jun-2015 | Current |
| Chinnasamy Anbarasu | Additional Director | 09-May-2024 | Current |
Financial Performance of Arizest Pharma (India).
Arizest Pharma (India) Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 0.94% increase. The company also saw a slight decrease in profitability, with a 1.29% decrease in profit. The company's net worth observed a substantial decline by a decrease of 13.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Arizest Pharma (India)?
In 2023, Arizest Pharma (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nitesh Residency Hotels Private LimitedActive 18 years 1 monthMakkigadde Shreepada is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 16 Dec 2020 | ₹40.00 Cr | Open |
How Many Employees Work at Arizest Pharma (India)?
Arizest Pharma (India) has a workforce of 18 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Arizest Pharma (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Arizest Pharma (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
